स्वास्थ्य सम्बन्धी सम्पूर्ण जानकारी

جميع المعلومات المتعلقة بالصحة

Lahat ng impormasyong may kaugnayan sa kalusugan

स्वास्थ्य संबंधी सारी जानकारी

Semua maklumat berkaitan kesihatan

ကျန်းမာရေးဆိုင်ရာ အချက်အလက်အားလုံး

ຂໍ້ມູນທີ່ກ່ຽວຂ້ອງກັບສຸຂະພາບທັງໝົດ

Dhammaan macluumaadka la xiriira caafimaadka

स्वास्थ्यसम्बद्धाः सर्वाणि सूचनानि

Alle gezondheidsgerelateerde informative

Tota la informació relacionada amb la salut

ሁሉም ከጤና ጋር የተያያዙ መረጃዎች

ព័ត៌មានទាក់ទងនឹងសុខភាពទាំងអស់។

صحت سے متعلق تمام معلومات

Mọi thông tin liên quan đến sức khỏe

The Health Thread Logo

The Health Thread

THT store

Listen to this audio

Recent developments in gene editing and personalized medicine have been revolutionizing the field of healthcare. Gene editing allows scientists to modify and edit specific genes, which has the potential to treat a variety of diseases and disorders. Personalized medicine, on the other hand, involves tailoring medical treatments to an individual’s unique genetic makeup. In this essay, we will explore the recent developments in gene editing and personalized medicine and their potential to transform healthcare.

Gene Editing:

CRISPR-Cas9 is a gene-editing technology that has been gaining a lot of attention in recent years. This technology allows scientists to precisely modify and edit specific genes. Researchers at the University of California, San Francisco, used CRISPR-Cas9 to edit the genes of mice with sickle cell disease, which is a genetic blood disorder. The study found that the edited cells produced healthy red blood cells, potentially leading to a cure for sickle cell disease (1). Another study by researchers at the University of Pennsylvania used CRISPR-Cas9 to edit genes in Tcells to treat cancer. The study found that the edited T-cells were able to target and kill cancer cells, leading to promising results in cancer treatment (2).

Personalized Medicine:

The field of personalized medicine involves using a patient’s genetic information to tailor medical treatments to their specific needs. Researchers at the Mayo Clinic conducted a study on personalized medicine for patients with Crohn’s disease, a chronic inflammatory bowel disease. The study found that patients who received personalized treatment based on their genetic information had better outcomes and fewer hospitalizations compared to those who received standard treatment (3). Another study by researchers at the University of California, San Diego, used genetic information to predict the risk of adverse drug reactions. The study found that using genetic information to personalize drug treatments could significantly reduce the risk of adverse drug reactions and improve patient outcomes (4).

Conclusion:

Gene editing and personalized medicine are rapidly advancing and have the potential to transform the field of healthcare. Gene editing allows for precise modification of specific genes, which has the potential to cure genetic diseases. Personalized medicine involves tailoring treatments to an individual’s unique genetic makeup, which can lead to better outcomes and fewer complications. As research in these fields continues to advance, we can expect to see even more innovative treatments and therapies.

REFERENCES

  • DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., … & Corn, J. E. (2016). Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Science translational medicine, 8(360), 360ra134-360ra134.
  • Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of chimeric antigen receptor T cells. Scientific reports, 7(1), 1-10.
  • Torkamani, A., Wineinger, N. E., & Topol, E. J. (2016). The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 19(9), 581-590.
  • Haga, S. B., Burke, W., Ginsburg, G. S., Mills, R., & Agans, R. (2012). Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clinical Genetics, 82(4), 388-394.